China Gender-affirming Hormone Therapy Study in Transgender Men and Women

What this Trial Is About

Researchers are studying transgender people in China who are beginning gender-affirming hormone therapy (GAHT) to better understand the physical and mental effects of this treatment. This research addresses the lack of data about GAHT in the Chinese transgender population, focusing on social, mental, and health impacts. The study includes transgender men and women diagnosed with gender dysphoria and aims to gather important evidence about their experiences and health changes. Participants will receive GAHT following international guidelines, with transgender men receiving testosterone undecanoate and transgender women receiving estradiol combined with antiandrogens such as spironolactone or cyproterone acetate. The study also includes healthy cisgender people for comparison. The hormone treatments are monitored over a 12-month period, with evaluations at baseline and during treatment to measure physical and psychological changes. During the study, participants will complete questionnaires about their life experiences, gender identity, and mental health. Researchers will assess insulin sensitivity, beta-cell function, bone density, depression, anxiety, suicide ideation, gender dysphoria, social exclusion, and brain function at various points. Safety is monitored through tracking any adverse effects, and participants are followed for a full year. The study aims to provide a comprehensive view of GAHT’s effects using detailed health and psychological assessments.

China Gender-affirming Hormone Therapy Study